JP2018512138A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512138A5 JP2018512138A5 JP2017550931A JP2017550931A JP2018512138A5 JP 2018512138 A5 JP2018512138 A5 JP 2018512138A5 JP 2017550931 A JP2017550931 A JP 2017550931A JP 2017550931 A JP2017550931 A JP 2017550931A JP 2018512138 A5 JP2018512138 A5 JP 2018512138A5
- Authority
- JP
- Japan
- Prior art keywords
- tim
- seq
- binding agent
- acid sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011230 binding agent Substances 0.000 claims 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims 24
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 102000004965 antibodies Human genes 0.000 claims 6
- 108090001123 antibodies Proteins 0.000 claims 6
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 4
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 4
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 4
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 4
- 102000018358 Immunoglobulins Human genes 0.000 claims 4
- 108060003951 Immunoglobulins Proteins 0.000 claims 4
- 102000015728 Mucins Human genes 0.000 claims 4
- 108010063954 Mucins Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000038129 antigens Human genes 0.000 claims 3
- 108091007172 antigens Proteins 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 206010003816 Autoimmune disease Diseases 0.000 claims 2
- 230000035693 Fab Effects 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000009910 diseases by infectious agent Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010011401 Crohn's disease Diseases 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 101710004393 HAVCR2 Proteins 0.000 claims 1
- 102100016384 HAVCR2 Human genes 0.000 claims 1
- 230000036499 Half live Effects 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 102100017213 LAG3 Human genes 0.000 claims 1
- 108060004270 LAG3 Proteins 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 208000002030 Merkel Cell Carcinoma Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 102100019764 PDCD1 Human genes 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 108060007796 SPATA2 Proteins 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 101700008936 Tim8 Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000002949 dengue disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000006704 ulcerative colitis Diseases 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562141353P | 2015-04-01 | 2015-04-01 | |
US62/141,353 | 2015-04-01 | ||
PCT/US2016/025532 WO2016161270A1 (en) | 2015-04-01 | 2016-04-01 | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018512138A JP2018512138A (ja) | 2018-05-17 |
JP2018512138A5 true JP2018512138A5 (de) | 2019-05-16 |
JP6949717B2 JP6949717B2 (ja) | 2021-10-13 |
Family
ID=57007695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017550931A Active JP6949717B2 (ja) | 2015-04-01 | 2016-04-01 | T細胞免疫グロブリン及びムチンタンパク質3(tim−3)に対する抗体 |
Country Status (15)
Country | Link |
---|---|
US (3) | US10508149B2 (de) |
EP (1) | EP3277321A4 (de) |
JP (1) | JP6949717B2 (de) |
KR (1) | KR20170133458A (de) |
CN (2) | CN107847589B (de) |
AU (1) | AU2016242964C1 (de) |
BR (1) | BR112017021040A2 (de) |
CA (1) | CA2981520A1 (de) |
EA (1) | EA201792184A1 (de) |
HK (1) | HK1251150A1 (de) |
IL (2) | IL283006B2 (de) |
MA (1) | MA41867A (de) |
MX (1) | MX2017012429A (de) |
SG (2) | SG11201707705UA (de) |
WO (1) | WO2016161270A1 (de) |
Families Citing this family (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9416132B2 (en) | 2011-07-21 | 2016-08-16 | Tolero Pharmaceuticals, Inc. | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors |
EP3049442A4 (de) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Verfahren zur behandlung von blutkrebs |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
CN107206071A (zh) | 2014-09-13 | 2017-09-26 | 诺华股份有限公司 | Alk抑制剂的联合疗法 |
HUE048111T2 (hu) | 2015-03-23 | 2020-05-28 | Bayer Pharma AG | Anti-CEACAM6 ellenanyagok és alkalmazásuk |
MA41867A (fr) * | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
MA45123A (fr) | 2016-05-27 | 2019-04-10 | Agenus Inc | Anticorps anti-tim-3 et leurs méthodes d'utilisation |
EP3468581A1 (de) | 2016-06-13 | 2019-04-17 | Torque Therapeutics, Inc. | Verfahren und zusammensetzungen zur förderung der immunzellenfunktionen |
RU2756236C2 (ru) | 2016-06-20 | 2021-09-28 | Кимаб Лимитед | PD-L1 специфические антитела |
PE20190418A1 (es) | 2016-07-14 | 2019-03-19 | Bristol Myers Squibb Co | Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos |
JOP20190013A1 (ar) | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
US11155624B2 (en) | 2016-11-01 | 2021-10-26 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
WO2018085469A2 (en) | 2016-11-01 | 2018-05-11 | Anaptysbio, Inc. | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
CN108101989A (zh) * | 2016-11-24 | 2018-06-01 | 复旦大学 | 针对人tim-3的全人源单域抗体及应用 |
JOP20190133A1 (ar) * | 2016-12-08 | 2019-06-02 | Innovent Biologics Suzhou Co Ltd | أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1 |
JP6839761B2 (ja) * | 2016-12-08 | 2021-03-10 | イーライ リリー アンド カンパニー | 抗PD−L1抗体との組み合わせのための抗Tim−3抗体 |
TWI665216B (zh) * | 2016-12-29 | 2019-07-11 | 財團法人生物技術開發中心 | 抗人類tim-3抗體及其使用方法 |
KR102606252B1 (ko) | 2017-01-09 | 2023-11-23 | 테사로, 인코포레이티드 | 항-pd-1 항체로 암을 치료하는 방법 |
MX2019008208A (es) * | 2017-01-09 | 2019-12-11 | Tesaro Inc | Métodos para tratar el cáncer con anticuerpos anti-tim-3. |
US11345753B2 (en) | 2017-02-27 | 2022-05-31 | Jiangsu Hengrui Medicine Co., Ltd. | TIM-3 antibody, antigen binding fragment thereof, and medicinal uses thereof |
MX2019012793A (es) | 2017-04-27 | 2020-02-13 | Tesaro Inc | Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos. |
AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
AU2018270112A1 (en) | 2017-05-18 | 2019-12-12 | Tesaro, Inc. | Combination therapies for treating cancer |
WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
CN110785187B (zh) | 2017-06-22 | 2024-04-05 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
JP2020524694A (ja) | 2017-06-22 | 2020-08-20 | ノバルティス アーゲー | がんの処置における使用のためのIL−1β結合性抗体 |
US20200223924A1 (en) | 2017-06-27 | 2020-07-16 | Novartis Ag | Dosage regimens for anti-tim-3 antibodies and uses thereof |
JP2020527572A (ja) | 2017-07-20 | 2020-09-10 | ノバルティス アーゲー | 抗lag−3抗体の投薬量レジメンおよびその使用 |
EP3658185A4 (de) | 2017-07-28 | 2021-07-14 | Phanes Therapeutics, Inc. | Anti-tim-3-antikörper und verwendungen davon |
KR20200044899A (ko) | 2017-08-28 | 2020-04-29 | 브리스톨-마이어스 스큅 컴퍼니 | 암의 치료 및 진단을 위한 tim-3 길항제 |
US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
CA3076907A1 (en) | 2017-09-26 | 2019-04-04 | Tesaro, Inc. | Niraparib formulations |
WO2019067978A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | POLYTHERAPIES FOR THE TREATMENT OF CANCER |
CN111182923A (zh) | 2017-10-06 | 2020-05-19 | 特沙诺有限公司 | 组合疗法及其用途 |
US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
BR112020008888A2 (pt) | 2017-11-16 | 2020-10-20 | Novartis Ag | terapias de combinação |
US20200371091A1 (en) | 2017-11-30 | 2020-11-26 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
TW201930591A (zh) | 2018-01-08 | 2019-08-01 | 瑞士商諾華公司 | 用於與嵌合抗原受體療法併用之免疫增強rna |
EP3746116A1 (de) | 2018-01-31 | 2020-12-09 | Novartis AG | Kombinationstherapie unter verwendung eines chimären antigenrezeptors |
WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
CN111886256A (zh) | 2018-03-23 | 2020-11-03 | 百时美施贵宝公司 | 抗mica和/或micb抗体及其用途 |
CN116789827A (zh) | 2018-04-12 | 2023-09-22 | 南京维立志博生物科技有限公司 | 应用tim-3结合抗体治疗疾病的方法 |
US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
KR20210003814A (ko) * | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질 |
UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
KR20210016390A (ko) | 2018-06-01 | 2021-02-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
US11192877B2 (en) | 2018-07-10 | 2021-12-07 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
EP3842071A4 (de) | 2018-08-20 | 2022-05-25 | Jiangsu Hengrui Medicine Co., Ltd. | Verwendung von tim-3-antikörper zur herstellung von arzneimitteln zur behandlung von tumoren |
CN112543647B (zh) | 2018-08-28 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | 一种tim3抗体药物组合物及其用途 |
TW202024638A (zh) * | 2018-09-04 | 2020-07-01 | 美商泰沙羅公司 | 治療癌症之方法 |
CA3113965A1 (en) | 2018-09-26 | 2020-04-02 | Astellas Pharma Inc. | Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy |
ES2967517T3 (es) | 2018-10-03 | 2024-04-30 | Tesaro Inc | Sales de niraparib |
EP3860988A1 (de) | 2018-10-03 | 2021-08-11 | Tesaro, Inc. | Kristalline formen der freien base von nirapaib |
KR20210099066A (ko) | 2018-12-04 | 2021-08-11 | 스미토모 다이니폰 파마 온콜로지, 인크. | 암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체 |
US20210340252A1 (en) * | 2018-12-12 | 2021-11-04 | WuXi Biologics Ireland Limited | Anti-tim-3 antibodies and uses thereof |
CA3123735A1 (en) | 2018-12-19 | 2020-06-25 | Bayer Aktiengesellschaft | Pharmaceutical combination of anti ceacam6 and tim3 antibodies |
WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
AU2019400980A1 (en) | 2018-12-20 | 2021-06-24 | Novartis Ag | Pharmaceutical combinations |
WO2020128637A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 binding antibodies in the treatment of a msi-h cancer |
EP3898974A1 (de) | 2018-12-21 | 2021-10-27 | Onxeo | Neue konjugierte nukleinsäuremoleküle und deren verwendungen |
US20200369762A1 (en) | 2018-12-21 | 2020-11-26 | Novartis Ag | Use of il-1beta binding antibodies |
US20230071889A1 (en) | 2018-12-21 | 2023-03-09 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
WO2020128613A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1beta binding antibodies |
CN113227138A (zh) | 2018-12-21 | 2021-08-06 | 诺华股份有限公司 | IL-1β结合抗体的用途 |
WO2020167990A1 (en) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
US20220144807A1 (en) | 2019-02-15 | 2022-05-12 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CN113329792A (zh) | 2019-02-15 | 2021-08-31 | 诺华股份有限公司 | 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置 |
WO2020198077A1 (en) | 2019-03-22 | 2020-10-01 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
WO2020192709A1 (en) * | 2019-03-27 | 2020-10-01 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific polypeptide complexes |
US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
EP3977132A1 (de) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Zelllokalisierungssignatur und kombinationstherapie |
EP3976832A1 (de) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Verfahren zur identifizierung eines für eine immunonkologe (i-o) therapie geeigneten subjekts |
JP2022537411A (ja) * | 2019-06-21 | 2022-08-25 | シングル セル テクノロジー, インコーポレイテッド | 抗tim-3抗体 |
US11529350B2 (en) | 2019-07-03 | 2022-12-20 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
AU2020337690A1 (en) | 2019-08-29 | 2022-04-07 | Astellas Pharma Inc. | Genetically engineered oncolytic vaccinia viruses and methods of uses thereof |
EP4041394A1 (de) | 2019-09-16 | 2022-08-17 | Novartis AG | Verwendung einer hochaffinen ligandenblockierenden humanisierten anti-t-zell-immunglobulin-domäne und eines mucin-domäne-3(tim-3)-igg4-antikörpers zur behandlung von myelofibrose |
JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
BR112022007376A2 (pt) | 2019-10-21 | 2022-07-05 | Novartis Ag | Terapias de combinação com venetoclax e inibidores de tim-3 |
TW202128191A (zh) | 2019-10-21 | 2021-08-01 | 瑞士商諾華公司 | Tim-3抑制劑及其用途 |
WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
IL293753A (en) | 2019-12-18 | 2022-08-01 | Tesaro Inc | Biopharmaceutical preparations and related methods |
US20230056470A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
CN114980902A (zh) | 2020-01-17 | 2022-08-30 | 诺华股份有限公司 | 用于治疗骨髓增生异常综合征或慢性粒单核细胞白血病的包含tim-3抑制剂和低甲基化药物的组合 |
CN115698075A (zh) * | 2020-04-14 | 2023-02-03 | 葛兰素史密斯克莱知识产权发展有限公司 | 涉及抗icos和抗pd1抗体,任选地进一步涉及抗tim3抗体的癌症的组合治疗 |
TW202214857A (zh) | 2020-06-19 | 2022-04-16 | 法商昂席歐公司 | 新型結合核酸分子及其用途 |
WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
EP4188549A1 (de) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroarylsubstituierte 3-(1-oxoisoindolin-2-yl)piperidin-2,6-dionderivate und verwendungen davon |
EP4204021A1 (de) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Verfahren zur behandlung von psma-exprimierenden krebsarten |
EP4204020A1 (de) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Verfahren zur behandlung von psma-exprimierenden krebsarten |
US20230303700A1 (en) | 2020-08-31 | 2023-09-28 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
IL302569A (en) | 2020-11-06 | 2023-07-01 | Novartis Ag | CD19 binding molecules and their uses |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
EP4267172A1 (de) | 2020-12-28 | 2023-11-01 | Bristol-Myers Squibb Company | Subkutane verabreichung von pd1/pd-l1-antikörpern |
PE20240820A1 (es) | 2020-12-28 | 2024-04-18 | Bristol Myers Squibb Co | Composiciones de anticuerpos y metodos de uso de los mismos |
WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
JP2024506557A (ja) | 2021-01-29 | 2024-02-14 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 修飾された腫瘍浸潤リンパ球を作製する方法及び養子細胞療法におけるそれらの使用 |
EP4314068A1 (de) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antikörper gegen gespaltenes cdcp1 und verwendungen davon |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
IL307419A (en) | 2021-04-09 | 2023-12-01 | Ose Immunotherapeutics | A new scaffold for bifunctional molecules with improved properties |
EP4320156A1 (de) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Gerüst für bifunctioanlmoleküle mit pd-1- oder cd28- und sirp-bindenden domänen |
TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
CA3230117A1 (en) | 2021-09-02 | 2023-03-09 | Mark Trautwein | Anti-cecam6 antibodies with reduced side-effects |
WO2023111203A1 (en) | 2021-12-16 | 2023-06-22 | Onxeo | New conjugated nucleic acid molecules and their uses |
WO2023130081A1 (en) | 2021-12-30 | 2023-07-06 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and vegf antagonist |
WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
WO2024102722A1 (en) | 2022-11-07 | 2024-05-16 | Neoimmunetech, Inc. | Methods of treating a tumor with an unmethylated mgmt promoter |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4828981A (en) | 1983-08-24 | 1989-05-09 | Synbiotics Corporation | Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
DE69128037T2 (de) | 1990-11-13 | 1998-05-07 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
EP0804590A1 (de) | 1993-05-21 | 1997-11-05 | Targeted Genetics Corporation | Bifunktionelle selektierbare fusionsgene auf dem cytosin-deaminase (cd) gen beruhend |
US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
WO2001057219A2 (en) | 2000-02-02 | 2001-08-09 | Schering Corporation | Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods |
FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
US20030103985A1 (en) | 2001-05-18 | 2003-06-05 | Boehringer Ingelheim International Gmbh | Cytotoxic CD44 antibody immunoconjugates |
AU2002357060A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
EP4091631A1 (de) * | 2002-01-30 | 2022-11-23 | The Brigham and Women's Hospital, Inc. | Ein tim-3 bindemolekül zur verwendung in der behandlung einer krankheit |
EP1501351A2 (de) * | 2002-04-17 | 2005-02-02 | Richard Metz | Homologe kurzfragment-substitution zur erzeugung von bse- resistenten rindern |
GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
SI2161336T1 (sl) | 2005-05-09 | 2013-11-29 | Ono Pharmaceutical Co., Ltd. | Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki |
US7824681B2 (en) | 2005-08-16 | 2010-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Human monoclonal antibodies that specifically bind IGF-II |
WO2008011348A2 (en) | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Humanized antibody against amyloid beta |
EP2074139B1 (de) | 2006-09-08 | 2013-10-23 | Amgen, Inc | Varianten der il-1-familie |
SI2805945T1 (sl) | 2007-01-10 | 2019-09-30 | Msd Italia S.R.L. | Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP) |
WO2008103475A1 (en) | 2007-02-20 | 2008-08-28 | Anaptysbio, Inc. | Somatic hypermutation systems |
EP2535354B1 (de) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antikörper gegen den humanen programmed death Rezeptor PD-1 |
RU2495035C2 (ru) | 2008-01-08 | 2013-10-10 | Мерк Шарп Энд Домэ Лтд | Фармацевтически приемлемые соли 2-{4-[(3s)-пиперидин-3-ил]фенил}-2н-индазол-7-карбоксамида |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
WO2009129247A2 (en) | 2008-04-14 | 2009-10-22 | Innovative Targeting Solutions Inc. | Sequence diversity generation in immunoglobulins |
RU2011105466A (ru) | 2008-08-28 | 2012-10-10 | ВАЙЕТ ЭлЭлСи (US) | Применения цитокинов семейств il-22, il-17 и il-1 при аутоиммунных заболеваниях |
PL2581113T3 (pl) * | 2010-06-11 | 2018-11-30 | Kyowa Hakko Kirin Co., Ltd. | Przeciwciało anty-tim-3 |
US9163087B2 (en) * | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
WO2013016220A1 (en) | 2011-07-22 | 2013-01-31 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
EP2748197A2 (de) * | 2011-08-26 | 2014-07-02 | Merrimack Pharmaceuticals, Inc. | Fc-bispezifische tandem-antikörper |
AP2014007571A0 (en) | 2011-11-16 | 2014-04-30 | Boehringer Ingelheim Int | Anti IL-36R antibodies |
CN102492038B (zh) * | 2011-12-09 | 2014-05-28 | 中国人民解放军军事医学科学院基础医学研究所 | 抗人Tim-3的中和性单克隆抗体L3D及其用途 |
WO2013098419A1 (en) | 2011-12-28 | 2013-07-04 | Immunoqure Ag | Method of providing monoclonal auto-antibodies with desired specificity |
MX364738B (es) | 2012-06-15 | 2019-05-03 | Pfizer | Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos. |
JP6162319B2 (ja) | 2013-03-12 | 2017-07-12 | デシミューン セラピューティクス,インコーポレイテッド | ヒト化抗n2抗体 |
JP6586016B2 (ja) | 2013-03-15 | 2019-10-02 | ノヴォ ノルディスク アー/エス | 組織因子系凝固インヒビター上の2つのエピトープに特異的に結合することが可能な抗体 |
DK2992017T3 (da) | 2013-05-02 | 2021-01-25 | Anaptysbio Inc | Antistoffer rettet mod programmeret død-1 (pd-1) |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
CR20160425A (es) | 2014-03-14 | 2017-05-26 | Novartis Ag | Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas |
GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
MX2017005920A (es) | 2014-11-06 | 2017-06-27 | Hoffmann La Roche | Anticuerpos anti-tim3 y metodos de uso. |
GB201421430D0 (en) | 2014-12-02 | 2015-01-14 | Medimmune Llc | Antibodies to Adam17 and uses thereof |
MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
MA41867A (fr) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
UA126272C2 (uk) | 2015-06-05 | 2022-09-14 | Дженентек, Інк. | Антитіло проти тау-білка та спосіб його застосування |
LT3317301T (lt) | 2015-07-29 | 2021-07-26 | Novartis Ag | Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3 |
BR112018008891A8 (pt) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos |
AR108377A1 (es) | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
WO2018085469A2 (en) | 2016-11-01 | 2018-05-11 | Anaptysbio, Inc. | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
MX2019008208A (es) * | 2017-01-09 | 2019-12-11 | Tesaro Inc | Métodos para tratar el cáncer con anticuerpos anti-tim-3. |
AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
-
2016
- 2016-03-31 MA MA041867A patent/MA41867A/fr unknown
- 2016-04-01 JP JP2017550931A patent/JP6949717B2/ja active Active
- 2016-04-01 KR KR1020177031599A patent/KR20170133458A/ko not_active Application Discontinuation
- 2016-04-01 US US15/563,924 patent/US10508149B2/en active Active
- 2016-04-01 SG SG11201707705UA patent/SG11201707705UA/en unknown
- 2016-04-01 CN CN201680031744.7A patent/CN107847589B/zh active Active
- 2016-04-01 WO PCT/US2016/025532 patent/WO2016161270A1/en active Application Filing
- 2016-04-01 EA EA201792184A patent/EA201792184A1/ru unknown
- 2016-04-01 BR BR112017021040A patent/BR112017021040A2/pt active Search and Examination
- 2016-04-01 SG SG10201909173P patent/SG10201909173PA/en unknown
- 2016-04-01 AU AU2016242964A patent/AU2016242964C1/en active Active
- 2016-04-01 EP EP16774301.2A patent/EP3277321A4/de active Pending
- 2016-04-01 MX MX2017012429A patent/MX2017012429A/es unknown
- 2016-04-01 CN CN202210219598.8A patent/CN114539409A/zh active Pending
- 2016-04-01 IL IL283006A patent/IL283006B2/en unknown
- 2016-04-01 CA CA2981520A patent/CA2981520A1/en active Pending
-
2017
- 2017-09-18 IL IL254559A patent/IL254559B2/en unknown
-
2018
- 2018-08-16 HK HK18110528.0A patent/HK1251150A1/zh unknown
-
2019
- 2019-10-17 US US16/655,939 patent/US11352427B2/en active Active
-
2022
- 2022-05-03 US US17/661,841 patent/US20220363759A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018512138A5 (de) | ||
JP2018505674A5 (de) | ||
JP2022031635A5 (de) | ||
JP2011509245A5 (de) | ||
HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
JP2019162105A5 (de) | ||
JP2019511212A5 (de) | ||
RU2016100892A (ru) | Антитела против tweakr и их применение | |
JP2009225799A5 (de) | ||
JP2013506428A5 (de) | ||
HRP20181069T1 (hr) | Antagonistička protutijela na il-17 | |
JP2018502060A5 (de) | ||
JP2019510733A5 (de) | ||
JP2019507135A5 (de) | ||
RU2017102514A (ru) | Гуманизированные анти-тау-антитела | |
JP2018532383A5 (de) | ||
JP2020508655A5 (de) | ||
JP2014511179A5 (de) | ||
JP2016533763A5 (ja) | ヒトpd−1に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
JP2018520993A5 (de) | ||
JP2010536384A5 (de) | ||
HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
JP2017535257A5 (de) | ||
JP2018537421A5 (de) | ||
JP2016529882A5 (de) |